

NO-A105 895


DEVELOPMENT OF NOVEL REVERSIBLE NON-TOXIC
ANTICOAGULANTS FOR GREATLY EXTENDED (U) EAST CAROLINA UNIV
SCHOOL OF MEDICINE GREENVILLE NC D T MILLER ET AL.
19 JUN 87 DAND17-86-C-6100 F/G 6/12

1/1

UNCLASSIFIED

NL





RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A

AD-A185 895

AD _____

DEVELOPMENT OF NOVEL, REVERSIBLE, NON-TOXIC ANTICOAGULANTS
FOR GREATLY EXTENDED PLATELET STORAGE

ANNUAL REPORT

David T. Miller and Arthur P. Bode

June 19, 1987

Supported by


U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND
Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-86-C-6180

East Carolina University School of Medicine
Greenville, North Carolina 27858

APPROVED FOR PUBLIC RELEASE:
DISTRIBUTION UNLIMITED

The findings in this report are not to be construed as an
official Department of the Army position unless so designated by
other authorized documents.



87 10 27 038

Objectives and Results

The objective of the first two years of this study is to formulate a new anticoagulant that minimizes platelet activation and the resultant storage lesion. It has been shown in this work and elsewhere, that plasma proteases, especially thrombin and plasmin, can cause changes in platelets similar to those typifying the storage lesion. We have tested numerous protease inhibitors and several inhibitors of platelet activation in an attempt to screen out compounds with irreversible or toxic effects on platelet function.

The design of the experiments was as follows. A selected compound was delivered in 3.5 mL of vehicle (citrate saline) into a 25 mL aliquot of fresh citrated PRP (n≥4) in a small PL-146 transfer bag. Another aliquot of the same PRP preparation was treated with vehicle alone and both were stored 24 hours under standard conditions. The next day, samples were drawn for assay of pH, pCO₂, pO₂, platelet count, hypotonic shock recovery, and aggregation with 2 x 10⁻⁵ ADP. If significant differences were noted between the treated PRP and the control, then both were centrifuged and resuspended in autologous plasma free of inhibitors and assayed again after a 2 hour incubation at 37°C. Table 1 gives examples of compounds showing reversible inhibition of platelet function. In Table 2 is presented data for compounds showing irreversible effects on platelets.

Table 1. Screening tests of compounds showing reversible inhibition of platelet function (means, n=4).

<u>Agent</u>	<u>Plt. Count</u>		<u>Hypotonic Shock</u>		<u>Aggregation</u>	
	<u>Pre</u>	<u>Post</u>	<u>Pre</u>	<u>Post</u>	<u>Pre</u>	<u>Post</u>
PGE-1 + theophylline ¹	96%	80%	63%*	73%	0*	61%
Control	94%	70%	84%	68%	64%	54%
Forskolin	97%	83%	48%*	55%	0*	116%
Control	102%	73%	59%	59%	80%	128%
Calla bulb extract	96%	ND	42%*	54%	5%*	49%
Control	97%	ND	82%	59%	77%	66%

"Pre"= after 24 hour incubation but prior to removal of inhibitor.

"Post"= after resuspension and incubation in inhibitor-free plasma.

All results reported as percent of value obtained with fresh PRP.

*Significantly different from control, p<0.05.

¹Five different doses tested, results from highest dose reported here.

Table 2. Screening tests of compounds showing irreversible effects on platelets (means, n≥4).

Agent	Plt. Count		Hypotonic Shock		Aggregation	
	Pre	Post	Pre	Post	Pre	Post
Fragmin ¹	64%	55%	83%	76%	73%	69%
Control	91%	73%	84%	91%	65%	79%

Unfractionated heparin - - platelets visibly clumped, testing impossible.

BABIM - - PRP clotted after 24 hour incubation.

Footnotes as in Table 1.

Many other compounds were tested and found to be without direct effect on platelet function. Below is given a brief summary of the results from preliminary storage studies using these agents singly or in combination.

- Vitamin E (α-tocopherol): No obvious beneficial effect in PC (n=4).
- Hydrocortisone: No obvious beneficial effect in PC (n=2).
- 5'AmidinoIndole: No obvious beneficial effect in PC (n=6).
- FUT-175: Insoluble in plasma, precipitates with phosphate ions, no obvious beneficial effect in PC (n=8).
- EACA: Slight beneficial effect in PC at high conc. (1 mM, n=8).
- Pepstatin A: No obvious beneficial effect in PC (n=4).
- Factor-deficient plasma: Infectivity risk to lab workers unacceptable.
- Garlic (allicin): Beneficial effect in PC lost after 24 hours (n=4).
- Leupeptin: Possible beneficial effect in PC, still under study.
- Hirudin: Definite beneficial effect in PC, very expensive.
- Thromstop: Definite beneficial effect in PC, less expensive alternative to hirudin, still under study.
- Aprotinin: Definite beneficial effect in PC, still under study.
- Thromboxane Synthetase inhibitors: To be tested.

Another compound of interest, DABE, is still unavailable to us. Apparently, the synthesis of DABE is extremely difficult. However, our success with other compounds from the lists above is not dependent on the availability of DABE.

In an attempt to limit the potential for bacterial growth in PC, we examined the effect of heparin and citrate based anticoagulant formulations including PGE-1 and theophylline on refrigerated platelets. Although all of the in vitro markers showed good preservation of platelet function for 10 days at 4°C, the platelets became irreversibly sphered, suggestive of poor transfusion quality. We have continually practiced careful arm scrub technique and discarded the first 10 mL of whole blood in order to limit bacterial contamination of PC. Every PC we study is examined at the end of the storage period by Gram stain. To date, none of our experimental PC has shown evidence of bacterial growth, and only a few of the controls have been positive.

New Anticoagulant

Our best results have been obtained with a formulation of:

CPDA-1 at 1:8 in whole blood plus
PGE-1 at 300 nM in whole blood plus
Theophylline at 1.9 mM plus
Aprotinin at 386 Kallikrein Inhibitor units/mL plus
Thromstop at 6 μ M or
Hirudin at 4 Antithrombin units/mL

The best results with this new anticoagulant were obtained at a surface-to-volume (S/V) ratio of 4 cm²/mL instead of the usual 7 cm²/mL. We were able to take advantage of a lower surface-to-volume ratio because of the lower metabolic rate evident in PC prepared in the presence of these inhibitors. A comparison of S/V ratios in PC stored in the new anticoagulant (without a thrombin inhibitor) for 15 days is given in Table 3. The S/V ratio was controlled by folding and clamping the PL-732 storage container prior to delivery of a measured volume of PC. The storage data for PC prepared in the complete anticoagulant and stored at a S/V ratio of 4 cm²/mL are presented in Table 4. These data show that, by in vitro markers, the platelets stored 15 days in this anticoagulant were comparable to standardly citrated PC stored 7 days. Citrated PC stored 15 days at a S/V ratio of 4 cm²/mL were as functionless as controls stored at 7 cm²/mL.

Table 3. Effect of surface-to-volume ratio on PC stored 15 days in CPDA-1 containing PGE-1 + theophylline + aprotinin (means, n=4).

<u>S/V Ratio</u>	<u>Plt. Count</u>	<u>pH</u>	<u>pCO₂</u>	<u>pO₂</u>	<u>Shock</u>
2 cm ² /mL	clumped	5.84	7	187	0 %
4 "	61 %	6.58	18	135	81 %
7 "	31 %	6.61	9	180	19 %

Platelet count and hypotonic shock recovery rate are reported as percent of value in PC at Day 0.

Table 4. Comparison of PC stored 15 days in CPDA-1 + PGE-1 + theophylline + aprotinin + Thromstop or hirudin to standard citrated PC (n≥4).

		<u>Count</u>	<u>pH</u>	<u>pCO₂</u>	<u>pO₂</u>	<u>Glucose</u>	<u>Shock</u>	<u>Agg-ADP</u>	<u>Discs</u>
CPDA-1	D7	80 %	6.84	24	104	209	82 %	22 %	55 %
Hirudin +	D15	67 %	6.46	29	85	118	87 %	42 %	70 %
Thromstop +	D15	70 %	6.55	25	103	126	66 %	76 %	68 %
CPDA-1	D15	64 %	<6.0	6	170	15	0 %	0 %	0 %

Platelet count, aggregation rate (in response to 2×10^{-5} ADP, with platelets resuspended in inhibitor-free plasma) and hypotonic shock recovery rate are expressed as a percent of the value for fresh PC at Day 0. Glucose levels are reported as mg/dL remaining in the PC plasma. Morphology is reported as percent of platelets appearing in discoid shape.

Storage of Platelet-rich Plasma

We have found that platelets stored as PRP instead of PC have better retention of in vitro responsiveness and viability during long-term storage experiments (see Table 5). The elimination of the second spin appears to avoid the initial activation of platelets and thus delay the onset of the storage lesion. Lowering the surface-to-volume ratio has been of benefit in the storage of PRP. We presume that this is permitted by a decreased metabolic rate relative to platelets in PC. Additional prolongation of the platelet shelf-life may be possible with supplementation of the citrate anticoagulant, as shown below with addition of PGE-1 and theophylline to CPDA-1. It may be possible to store platelets for 20 days with this methodology.

Table 5. Storage data for PRP at reduced S/V ratios (means, n=8).

		<u>Count</u>	<u>pH</u>	<u>pCO₂</u>	<u>pO₂</u>	<u>Glucose</u>	<u>Shock</u>	<u>Agg-ADP</u>
CPDA-1	D15	86 %	6.91	37	158	198	45 %	26 %
S/V=1.8	D20	75 %	6.64	23	178	140	7 %	14 %
PGE-1+Theo	D15	78 %	7.03	45	86	253	88 %	ND
S/V=1.8	D20	57 %	6.82	38	125	190	45 %	20 %
CPDA-1	D15	61 %	6.90	40	103	ND	60 %	39 %
S/V=1.3	D20	53 %	6.70	28	159	ND	25 %	16 %

Footnotes as in other tables.

Future Directions

Our continuing goal is to formulate a new anticoagulant strategy for preservation of platelet function and viability for at least 15 days. We have learned thus far that a combination of platelet activation inhibitors, a thrombin inhibitor, and a plasmin inhibitor work well together as supplements to CPDA-1. Further refinements may be necessary, such as use of a thromboxane synthetase inhibitor to reinforce the inhibitory activity of the cyclic AMP-active agents already employed. Inhibitors of calcium-activated proteases (ex., leupeptin) may also be of some benefit. However, the success achieved with the current formulation is not dependent on these refinements.

The surface-to-volume ratio currently used by blood banks in routine PC storage (approx. 7 cm²/mL) has proved to be less than optimal in the storage of platelets in the new anticoagulant. There is a detrimental effect on stored platelets when the S/V ratio is too high, probably because of the rate of contact of platelets with the bag wall. Our preliminary data indicates that storage of either PC or PRP can benefit from reduced S/V ratios. We will continue these efforts to optimize the bag geometry for each preparation based on the metabolic demands of the platelets being stored.

We would like to suggest the consideration of two separate products for transfusion therapy: PRP and PC. It appears that platelets stored as PRP have the potential for greatly prolonged shelf-life with minimal chemical supplementation. PRP could serve as a forward resuscitation fluid for combat casualties who would not be compromised by the extra volume (relative to PC). PC would still be appropriate for post-op transfusion therapy.

Because of the very encouraging data generated thus far during 15 days of storage of PC or PRP in the new anticoagulant, we would like to start the survival studies ahead of the efficacy studies. We had originally planned to do efficacy studies in thrombocytopenic rabbits during Year 3 and then proceed to platelet survival studies in baboons in Year 4. One advantage in changing this schedule would be that we could assess the impact of the new anticoagulant formulations on platelet survivals over two years of testing (Years 3 and 4) and adjust components and concentrations accordingly. Another advantage would be the ability to study the effects of repeated transfusions of inhibitor-treated platelets in the baboons over a period of time that should reveal problems (if any) with antigenicity of the compounds in the anticoagulant. We would appreciate the reader's thoughts on this proposed change in work schedule.

In sum, we have produced an anticoagulant strategy that works well by in vitro assessment in the storage of platelets for 15 days. We plan to further refine the choice and concentration of reagents used in this strategy during the second year of this project. We hope that the USAMRDC is pleased with our progress.

DISTRIBUTION LIST

4 copies Commander
Letterman Army Institute of
 Research (LAIR), Bldg. 1110
ATTN: SGRD-ULZ-RC
Presidio of San Francisco, CA 94129-6815

1 copy Commander
US Army Medical Research and Development Command
ATTN: SGRD-RMI-S
Fort Detrick, Frederick, Maryland 21701-5012

12 copies Defense Technical Information Center (DTIC)
ATTN: DTIC-DDAC
Cameron Station
Alexandria, VA 22304-6145

1 copy Dean
School of Medicine
Uniformed Services University of the
 Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814-4799

1 copy Commandant
Academy of Health Sciences, US Army
ATTN: AHS-CDM
Fort Sam Houston, TX 78234-6100

ADA 185895

REPORT DOCUMENTATION PAGE

Form Approved
OMB No 0704-0188
Exp Date Jun 30, 1986

1a REPORT SECURITY CLASSIFICATION Unclassified			1b RESTRICTIVE MARKINGS			
2a SECURITY CLASSIFICATION AUTHORITY			3 DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; distribution unlimited			
2b DECLASSIFICATION/DOWNGRADING SCHEDULE			4 PERFORMING ORGANIZATION REPORT NUMBER(S)			
4 PERFORMING ORGANIZATION REPORT NUMBER(S)			5 MONITORING ORGANIZATION REPORT NUMBER(S)			
6a. NAME OF PERFORMING ORGANIZATION East Carolina University School of Medicine		6b OFFICE SYMBOL (if applicable)		7a NAME OF MONITORING ORGANIZATION		
6c. ADDRESS (City, State, and ZIP Code) Greenville, North Carolina 27858				7b ADDRESS (City, State, and ZIP Code)		
8a. NAME OF FUNDING/SPONSORING ORGANIZATION Research & Development Command		8b OFFICE SYMBOL (if applicable) SGRD-RMI-S		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-86-C-6180		
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-9012				10. SOURCE OF FUNDING NUMBERS		
		PROGRAM ELEMENT NO. 62772A		PROJECT NO. 3S162772A874		WORK UNIT ACCESSION NO. 267
		TASK NO. AD				
11. TITLE (Include Security Classification) Development of Novel, Reversible, Non-Toxic Anticoagulants for Greatly Extended Platelet Storage						
12. PERSONAL AUTHOR(S) Miller, David T. and Bode, Arthur P.						
13a. TYPE OF REPORT Annual		13b TIME COVERED FROM 4/7/86 TO 4/6/87		14 DATE OF REPORT (Year, Month, Day) June 19, 1987		15. PAGE COUNT 9
16. SUPPLEMENTARY NOTATION						
17. COSATI CODES			18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number)			
FIELD	GROUP	SUB-GROUP	Human blood donors; anticoagulants; platelet concentrates; protease inhibitors; platelet activation inhibitors; plasmin; thrombin; surface-to-volume ratio; cyclic AMP; storage lesion			
06	01					
06	05					
19 ABSTRACT (Continue on reverse if necessary and identify by block number) The first phase of the development of a new anticoagulant formulation for extended storage of platelets is largely complete. Compounds which inhibit plasma proteases or platelet activation were screened for irreversible effects on platelets in short-term storage studies. Several combinations of reversible compounds were used as new anticoagulant formulations in long term storage studies which showed remarkable improvements in platelet viability by in vitro markers for up to 14 days at room temperature. The best results were obtained with the combined strategy of: elevation of cyclic AMP (cPGI-1 plus theophylline), inhibition of plasmin and contact activation (aprotinin), and inhibition of thrombin (hirudin or thrombol). Platelets stored with these inhibitors showed signs of a lowered metabolic load and therefore could be contained in bags with a reduced surface-to-volume ratio. Further studies will be undertaken to finalize the formulation and bag geometry before proceeding to toxicity and efficacy studies in animal models.						
20 DISTRIBUTION/AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS				21 ABSTRACT SECURITY CLASSIFICATION Unclassified		
22a NAME OF RESPONSIBLE INDIVIDUAL Mary E. Portian			22b TELEPHONE (Include Area Code) 301 7663-7325		22c OFFICE SYMBOL SGRD-RMI-S	

END
DATE
FILMED
JAN
1988